Results 91 to 100 of about 5,903 (227)

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1368-1381, September 2026.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [PDF]

, 2007
Background: Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases.
Moosmann, Nicolas, Schulz, Christoph, Laessig, Dorit, Michaely, Henrik Jakob, Heinemann, Volker   +4 more
core   +1 more source

Potential Survival Benefit of Adjuvant Chemotherapy in Stage IV Intrahepatic Cholangiocarcinoma: A Multicenter, Stage‐Stratified Analysis

Annals of Gastroenterological Surgery
Background The survival benefit of adjuvant chemotherapy (AC) in intrahepatic cholangiocarcinoma (ICC) remains uncertain, particularly in advanced‐stage disease.
Hisashi Kosaka, Masaki Ueno, Hiroji Shinkawa, Yusuke Yamamoto, Masahiko Kinoshita, Koji Komeda, Tsukasa Aihara, Satoshi Yasuda, Haruki Mori, Masaki Kaibori   +9 more
doaj   +1 more source

A Case of Diffuse Alveolar Hemorrhage Associated with Tegafur plus Uracil and Warfarin Therapy

Clinical Medicine Insights: Case Reports, 2011
A 72-year-old man who received warfarin for myocardial infarction (prothrombin time-international normalized ratio [PT-INR] controlled between 2.2 and 2.5) for 2 years.
Masayuki Itoh, Shuji Oh-ishi, Kenji Nemoto, Seitaro Senba, Hideki Adachi, Koji Kishi, Hiroyuki Nakamura, Harumi Takahashi   +7 more
doaj   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

Annals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1507-1517, September 2026.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu, Yoshiyuki Tagayasu, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Yukio Fujiwara, Kazuto Harada, Keisuke Kosumi, Yoshifumi Baba, Masaaki Iwatsuki   +9 more
wiley   +1 more source

Oral fluoropyrimidines in colorectal cancer: a door open to the future?

, 2004
Since its first use 40 years ago, 5-fluorouracil (5-FU) has become an unquestionable component of colorectal cancer treatment. It is also now well established that infusional 5-FU administration, in combination with leucovorin, is associated with better ...
Delaunoit, Thierry, Eisendrath, Pierre, Hendlisz, Alain, Neczyporenko, Florence, Bleiberg, Harry   +4 more
core  

Individualized dosing of fluoropyrimidines by genotyping and phenotyping of dihydropyrimidine dehydrogenase [PDF]

, 2018
The class of fluoropyrimidine anticancer drugs includes 5-fluorouracil and capecitabine. These drugs are used by an estimated two million patients yearly worldwide and are the cornerstone of chemotherapeutic treatment of several solid tumor types ...
Pharmacoepidemiology and Clinical Pharmacology, Henricks, Linda M   +1 more
core  

Predicting the Efficacy of Adjuvant Chemotherapy Using Immuno‐Nutritional and Inflammatory Markers in Elderly Patients With Stage III Colorectal Cancer

Annals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1575-1585, September 2026.
This study aimed to determine whether immuno‐nutritional and inflammatory markers could serve as predictors of the outcomes of postoperative adjuvant chemotherapy for stage III colorectal cancer in elderly patients. Postoperative lymphocyte‐to‐monocyte ratio and postoperative C‐reactive protein‐to‐albumin ratio accurately predicted the efficacy of ...
Tomoya Tago, Yasuyuki Takamizawa, Takeharu Kato, Hiroshi Nagata, Konosuke Moritani, Shunsuke Tsukamoto, Yukihide Kanemitsu   +6 more
wiley   +1 more source

Heidelberger symposium on the 50th anniversary of fluoropyrimidines [PDF]

Molecular Cancer Therapeutics, 2009
“Targeted” therapies are dominating new cancer therapeutics during the past decade. However, the term is not precise because drugs referred to as “cytotoxics” are often targeted, and drugs developed as targeted often exert many of their antitumor actions by “off-target” effects; that ...
openaire   +2 more sources

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 2986-3001, September 2026.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source